ST2 provides new insight on cardiovascular disease progression—relevant disease state information not reflected by other biomarkers and clinical observations.

Multiple published studies by leading investigators from around the world have demonstrated that ST2 is a powerful prognostic cardiac biomarker available, and when used in conjunction with other clinical parameters, which may help physicians make better clinical decisions.

ST2 is most useful in determining the patient's likely prognosis, regardless of their symptom status. Furthermore, ST2 enhances prognosis when used in conjunction with natriuretic peptide markers.